SCPX (Scorpius Holdings) Cyclically Adjusted Revenue per Share: $223.76 (As of Sep. 2025)


What is Scorpius Holdings Cyclically Adjusted Revenue per Share?

Scorpius Holdings SCPX +83.33% Cyclically Adjusted Revenue per Share is $223.76 as of Sep. 2025. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Scorpius Holdings's adjusted revenue per share for the three months ended in Sep. 2025 was $0.004. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $223.76 for the trailing ten years ended in Sep. 2025.

During the past 12 months, Scorpius Holdings's average Cyclically Adjusted Revenue Growth Rate was -9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-12), Scorpius Holdings's current stock price is $0.0022. Scorpius Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2025 was $223.76. Scorpius Holdings's Cyclically Adjusted PS Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Scorpius Holdings was 1.92. The lowest was 0.01. And the median was 0.49.


Scorpius Holdings  (OTCPK:SCPX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Scorpius Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.0022/223.76
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Scorpius Holdings was 1.92. The lowest was 0.01. And the median was 0.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Scorpius Holdings Cyclically Adjusted Revenue per Share Related Terms


Scorpius Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Scorpius Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scorpius Holdings Cyclically Adjusted Revenue per Share Chart

Scorpius Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 288.59 262.06 238.46

Scorpius Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 246.12 238.46 234.08 228.95 223.76

SCPX vs CARM, CYTOF, CNBX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Scorpius Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scorpius Holdings Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's Cyclically Adjusted PS Ratio falls into.



Scorpius Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Scorpius Holdings's adjusted Revenue per Share data for the three months ended in Sep. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2025 (Change)*Current CPI (Sep. 2025)
=0.004/324.8000*324.8000
=0.004

Current CPI (Sep. 2025) = 324.8000.

Scorpius Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 236.525 0.000
201603 0.000 238.132 0.000
201606 0.000 241.018 0.000
201609 220.000 241.428 295.972
201612 60.500 241.432 81.391
201703 12.000 243.801 15.987
201706 0.000 244.955 0.000
201709 157.000 246.819 206.603
201712 204.667 246.524 269.653
201803 251.000 249.554 326.682
201806 103.909 251.989 133.933
201809 108.235 252.439 139.260
201812 89.478 251.233 115.679
201903 29.208 254.202 37.320
201906 14.250 256.143 18.070
201909 0.250 256.759 0.316
201912 83.292 256.974 105.276
202003 22.000 258.115 27.684
202006 9.413 257.797 11.859
202009 8.252 260.280 10.298
202012 5.336 260.474 6.654
202103 4.455 264.877 5.463
202106 3.643 271.696 4.355
202109 0.000 274.310 0.000
202112 0.000 278.802 0.000
202203 1.656 287.504 1.871
202206 0.398 296.311 0.436
202209 0.461 296.808 0.504
202212 0.625 296.797 0.684
202303 5.892 301.836 6.340
202306 5.062 305.109 5.389
202309 5.562 307.789 5.869
202312 37.292 306.746 39.487
202403 24.922 312.332 25.917
202406 2.310 314.175 2.388
202409 0.131 315.301 0.135
202412 0.421 315.605 0.433
202503 0.023 319.799 0.023
202506 0.005 322.561 0.005
202509 0.004 324.800 0.004

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $223.76 mean?
Scorpius Holdings (SCPX) has a Cyclically Adjusted Revenue per Share of $223.76 as of Sep. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scorpius Holdings and its competitors.
Is Scorpius Holdings' Cyclically Adjusted Revenue per Share too high?
Scorpius Holdings' current Cyclically Adjusted Revenue per Share is $223.76.
How does Scorpius Holdings' Cyclically Adjusted Revenue per Share compare to CARM and CYTOF?
Scorpius Holdings' Cyclically Adjusted Revenue per Share of $223.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scorpius Holdings and its competitors. Scorpius Holdings's current Cyclically Adjusted Revenue per Share is $223.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scorpius Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scorpius Holdings (SCPX) is currently considered Possible Value Trap. The stock's GF Value™ is $0.14, compared to a current price of $0.00 — trading 98.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $223.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Scorpius Holdings (SCPX), the current Cyclically Adjusted Revenue per Share is $223.76 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scorpius Holdings Business Description

Address 1305 East Houston Street, San Antonio, TX, USA, 27560
Scorpius Holdings Inc is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state of the art facilities.